Business
In this episode of Denatured, you’ll be listening to Jane Hughes, President of R&D and Co-founder of Verdiva Bio, and Jon Rees, CEO and Co-founder of MitoRx Therapeutics. We’ll discuss next-generation obesity solutions tackling GLP-1’s muscle loss and adherence challenges, through innovative muscle preservation, oral administration and combination therapy.
FEATURED STORIES
An analysis finds that pharmas frequently file multiple similar patents on drugs, then use them as the basis for questionable litigation against would-be competitors.
The limited supply of this common reagent is set to drive drug prices higher, but there are ways for companies to lessen the impact.
Suppliers are investing in production to support deals with AstraZeneca, Bayer and other drugmakers that are advancing radioisotope-based cancer therapies.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Three months after Chief Executive Officer Mark Pruzanski exited Intercept, the company’s chief medical officer is also leaving.
The launch of Fore Biotherapeutics in the U.S. reflects an evolved biotech business model focused on matching patients with unaddressed tumor mutations with the right oncology medicines in the clinic, the company said.
The AMR Action Fund is ramping up its infrastructure – announcing yesterday that former Novartis Venture Funds Head, Henry Skinner, will take the helm as the organization’s first chief executive officer.
The new company, FS Development II, announced this week it raised $175 million in an upsized offering at $10 per share. The shares will be listed on the Nasdaq under the ticker symbol FSII.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Eli Lilly is jumping into the RIPK1 chase, paying $125 million up front to partner with Rigel Pharmaceuticals to co-develop its lead RIPK1 inhibitor program across all indications.
BeiGene’s Bruton’s kinase inhibitor Brukinsa (zanabrutinib) could be on its way for regulatory approval as a potential treatment for Waldenström’s macroglobulinemia (WM), a type of non-Hodgkin lymphoma.
Nektar Therapeutics has entered into a financing and co-development collaboration with SFJ Pharmaceuticals which will advance the development of investigational CD122-preferential IL-2–pathway agonist bempegaldesleukin for head and neck cancer.
The company announced this morning it is merging with special purpose acquisition company Alpha Healthcare Acquisition Corp. and will begin trading on the Nasdaq exchange under the ticker symbol “HUMA” in the second quarter of 2021.
The Foundation will offer funding for development of the therapy.